CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
Simple Summary
Roberto, M.; Astone, A.; Botticelli, A.; Carbognin, L.; Cassano, A.; D’Auria, G.; Fabbri, A.; Fabi, A.; Gamucci, T.; Krasniqi, E.; Minelli, M.; Orlandi, A.; Pantano, F.; Paris, I.; Pizzuti, L.; Portarena, I.; Salesi, N.; Scagnoli, S.; Scavina, P.; Tonini, G.; Vici, P.; Marchetti, P. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers 2021, 13, 332. https://doi.org/10.3390/cancers13020332
Roberto M, Astone A, Botticelli A, Carbognin L, Cassano A, D’Auria G, Fabbri A, Fabi A, Gamucci T, Krasniqi E, Minelli M, Orlandi A, Pantano F, Paris I, Pizzuti L, Portarena I, Salesi N, Scagnoli S, Scavina P, Tonini G, Vici P, Marchetti P. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers. 2021; 13(2):332. https://doi.org/10.3390/cancers13020332
Chicago/Turabian StyleRoberto, Michela, Antonio Astone, Andrea Botticelli, Luisa Carbognin, Alessandra Cassano, Giuliana D’Auria, Agnese Fabbri, Alessandra Fabi, Teresa Gamucci, Eriseld Krasniqi, Mauro Minelli, Armando Orlandi, Francesco Pantano, Ida Paris, Laura Pizzuti, Ilaria Portarena, Nello Salesi, Simone Scagnoli, Paola Scavina, Giuseppe Tonini, Patrizia Vici, and Paolo Marchetti. 2021. "CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives" Cancers 13, no. 2: 332. https://doi.org/10.3390/cancers13020332